Abstract: There is provided a multi-layered sheet mask comprising at least (a) a porous first layer having a first side and a second side, wherein the first side is opposite to the second side, and comprises a plurality of three-dimensional patterns extending therefrom; (b) a second layer attached to the second side of the porous first layer, the second layer comprising at least one pouch for receiving or containing at least one first active ingredient; a porous support structure; an air pouch that is sandwiched between the second side of the porous first layer and the porous support structure; and a plurality of microchannels that extend from the pouch and beyond the first side of the porous first layer when the air pouch is deflated; and (c) a third layer attached to the second layer for receiving or containing at least one second active ingredient.

Abstract: According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.

Abstract: According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.

Abstract: An occlusion device for closing an anatomical defect in tissue comprising a conduit connecting an opening on a first tissue and an opening on a second tissue is provided. The occlusion device comprises a scaffold comprising a) a proximal support structure comprising at least two arms; b) a distal support structure comprising at least two arms, wherein the arms are adapted to provide anchorage for the device in the tissue; and c) a waist portion adapted for extending through the opening on the first tissue and connecting the proximal support structure with the distal support structure, wherein the scaffold consists essentially of a biodegradable polymer, wherein the proximal support structure and the distal support structure comprise or consist of polycaprolactone (PCL), poly-(D,L-lactide-co-caprolactone) (PLC), or a mixture thereof. A method of closing an anatomical defect using the occlusion device is also provided.

Abstract: The present invention generally relates to the field of transcatheter device closure techniques for closing an opening in a tissue and more particularly, to occlusion devices for closing anatomical defects in tissue such as defects consisting of an opening connecting a front side and a back side of a tissue. More particularly the present invention relates to occlusion devices for closing septal abnormalities such as atrial septal defects and patent foramen ovale, delivering systems for such occlusion devices, kits comprising the occlusion devices and the delivering systems and to methods of closing an anatomical defect in a tissue consisting of an opening connecting a front side and a back side of a tissue.

Abstract: Provided is a glaucoma valve, a casing for containing a glaucoma valve and a glaucoma drainage device including the glaucoma valve and/or the casing. The valve includes a flow channel having an inlet and an outlet and a valve member connected to the outlet of the flow channel. The valve member may be formed from a degradable polymer or a combination of degradable polymer and non-degradable polymer. The valve may have a first flow channel, the interior of which may be coated with a degradable polymer, such that in use, the polymer degrades to allow a greater flow of fluid through the flow channel. The valve may include a second flow channel, which may be arranged in parallel to the first flow channel. The casing may be formed from a degradable polymer, such as a biodegradable polymer.

Abstract: According to the present disclosure, the use of a liposomal formulation comprising one or more phospholipids in the manufacture of a medicament, or in a method for the treatment of posterior and/or anterior ocular segment diseases is provided. Preferred phospholipids include POPC and DOTAP, POPC and POPG, DPTAP and POPG, DMTAP and POPG, DPPC and DPTAP, DPPC and DPPG, DMPC and DMTAP, or DMPC and DMPG. In a separate embodiment, the use of a particulate formulation comprising a plurality of poly(lactic-co-glycolic acid) particles in the manufacture of a medicament, or in a method for the treatment of posterior and/or anterior ocular segment diseases is also provided. In either embodiments, the posterior ocular segment diseases comprise age related degeneration, diabetic macular edema or retinopathy and anterior ocular segment diseases comprise glaucoma, cataract or uveitis.

Abstract: The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2???. The present invention is also directed to a pharmaceutical comprising the liposomal formulation and a method of producing the liposomal formulation for ocular drug delivery. Additionally, the present invention is directed to a method of treating or preventing an ocular disease, comprising administering the liposomal formulation or the pharmaceutical composition to a subject in need thereof.

Abstract: According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.

Abstract: The present invention relates to a method for forming a tissue construct having a composite structure. The method includes providing a biodegradable substrate, wherein the substrate is adapted to allow deposition or growth of a plurality of cells; providing a vascularized layer comprising a plurality of blood vessels therein; and adhering the vascularized layer to the substrate.

Abstract: Present invention relates to a device for controlled release of a bioactive agent. The device comprises a thin film located on the surface of the device, wherein said thin film comprises a bioactive agent-containing layer comprising a polymeric matrix and at least one bioactive agent.

Abstract: Provided is a biodegradable ocular implant for sustained drug delivery, including a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.

Abstract: An energy charge storage device, particularly from the group consisting of super capacitor, a hybrid electrochemical capacitor, a metal hydride battery and a fuel cell, comprising a first and second electrode and an electrolyte wherein the electrolyte comprises a printable polyelectrolyte e.g. polystyrene sulfonic acid (PSSH). The present invention also refers to methods of obtaining such energy storage device.

Abstract: Various embodiments relate to the field of liposomal formulations for drug delivery, in particular, liposomal formulations for ocular drug delivery. More specifically, various embodiments relate to sustained timolol maleate delivery from liposomes for glaucoma therapy and ocular hypertension.

Abstract: The present invention refers to an electrode comprised of a first layer which comprises a mesoporous nanostructured hydrophobic material; and a second layer which comprises a mesoporous nanostructured hydrophilic material arranged on the first layer. In a further aspect, the present invention refers to an electrode comprised of a single layer which comprises a mixture of a mesoporous nanostructured hydrophobic material and a mesoporous nanostructured hydrophilic material; or a single layer comprised of a porous nanostructured material wherein the porous nanostructured material comprises metallic nanostructures which are bound to the surface of the porous nanostructured material. The present invention further refers to the manufacture of these electrodes and their use in metal-air batteries, supercapacitors and fuel cells.

Abstract: The present invention generally relates to the field of prostheses for surgical applications, to methods of their manufacturing and to methods of treating a patient by implanting them into a patient. More particularly, the present invention relates to prostheses having a multi-layered sheet structure and their use in hernia repair, the repair of anatomical defects of the abdominal wall, diaphragm, and chest wall, correction of defects in the genitourinary system, and repair of traumatically damaged organs such as the spleen, liver or kidney.

Abstract: The present invention is directed to a hybrid device comprising: an energy converting unit comprising a first electrode, a second electrode and an energy converting medium arranged between the first electrode and the second electrode, wherein the energy conversion takes place between the first electrode and the second electrode; an energy charge storing unit comprising a first electrode, a second electrode and an electrolyte medium; wherein the energy charge is stored between the first and the second electrode; the second electrode of the energy converting unit and the second electrode of the energy charge storing unit being a shared electrode electrically connecting the energy converting unit and the energy charge storing unit; and wherein the shared electrode comprises a metal and a nanostructured material. The present invention is also directed to a method of manufacturing such a hybrid device.

Abstract: A laparoscopic tool, the tool including an elongate shaft; a handle at one end of the shaft and an aperture at the opposed end, and; a tape selectively extendable from the aperture.

Abstract: A method forms a bimetallic core-shell nanostructure. The bimetallic core-shell nanostructure comprises a core comprising silver and a shell comprising gold. The bimetallic core-shell nanostructure may be used in various technical fields, such as surface-enhanced Raman scattering (SERS), photovoltaic cells, biomedical, bioimaging and biosensing applications.

Abstract: Provided is a biodegradable ocular implant for sustained drug delivery, including a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.